Home > Insider Trading > Filing (0000899243-22-016310)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1888012	Hillevax Inc.	HLVX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1341382	N James Topper	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1365617	J Patrick Heron	601 Union Street, Suite 3200 Seattle WA 98101	Yes	No	Yes	No
1790811	Fhmls X, L.l.c.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1790879	Frazier Life Sciences X, L.p.	601 Union Street, Suite 320 Seattle WA 98101	No	No	Yes	No
1790880	Fhmls X, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-05-03	2,736,234	$13.60	6,770,631	No	4	C	Direct
Common Stock	Acquisiton	2022-05-03	1,764,706	$17.00	8,535,337	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Convertible Promissory Notes	Disposition	2022-05-03	37,212,796	$0.00	2,736,234	$13.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct

Footnotes

The securities are held directly by Frazer Life Sciences X, L.P. ("FLS X"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
The outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock immediately prior to the closing of the initial public offering at a conversion price of $13.60 per share.